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Abstract
Background: We have previously reported the induction of many interferon stimulated genes (ISGs) in PBMC
collected from patients infected with HCV at various times after initiation of interferon-ribavirin treatment using
DNA microarrays to identify changes in gene expression with time. Almost as many genes are down regulated
(suppressed) during interferon-ribavirin treatment as are up regulated.
Methods: DNA microarrays were analyzed by different software, including MAS5 (Affymetrix-Kegg) and GSEA (gene
set enrichment analysis) to identify specific pathways both up regulated and down regulated. Data was assessed
from a clinical trial, which was a microarray analysis from 68 patients.
Results: Up regulated genes included genes associated with NF-kb, toll like receptor cytokine -cytokine interaction,
and complement and adhesion pathways. The most prominent pathway down regulated was that for ribosomal
structural proteins, and eukaryotic translational factors. Down regulation of ribosomal protein genes continued
through the treatment up to the last measurement, which was at day 28.
Conclusions: This suppression of the protein synthetic apparatus might explain the long-term side effects of
interferon-ribavirin, and explain a non-specific effect of interferon-ribavirin on viral protein synthesis. There was no
evidence for unique transcription factors or micro RNA involvement.
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Introduction
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sas i g n i f i c a n tg l o b a l
public health problem, affecting approximately 150 million
individuals worldwide and over 4 million in the United
States alone, where it is the predominant blood-borne
infection [1]. It is currently the leading indication for a
liver transplant and is responsible for 8,000-10,000 deaths
annually. Treatment with Interferon -a has formed the
backbone of therapy against HCV, first as mono-therapy,
then in combination with the nucleoside analogue riba-
virin. Current standard of care for chronic HCV infection
consists of a regimen of pegylated interferon in combina-
tion with ribavirin and more recently the addition of a
protease inhibitor [2]. The combination of pegylated IFN-
alpha and ribavirin successfully eradicates the virus from
50-60% of those treated depending on antigenic strain of
the virus and race of the patient. Genotype 1a and 1 b the
most prevalent genotypes in the USA are the most difficult
to eradicate, and the sustained response rate among Afri-
can Americans is lower than that found in other racial
groups [3].
Conventional analysis of DNA microarrays between
control (before treatment) and interferon treated samples
results in large lists of genes induced or down regulated
that in many cases appear to be unconnected [4,5]. In the
typical experiment one looks for fold increases in expres-
sion of specific genes, using paired Student’s t-test to
assess significance between the different treatments (or
classes). We have reported that approximately 1,000
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from PBMC of hepatitis C patients being treated with
Pegasys/ribavirin [5] using a 1.5 fold cut off and a p value
of < 0.001. Utilizing a mathematical approach in which
we compared clustering of patient response with gene
expression we have identified 36 genes that appear to be
closely correlated with the antiviral response [6] An alter-
native method of analyzing microarrays, called gene set
enrichment analysis (GSEA) has been published. This
approach utilizes our knowledge of specific pathways,
chromosomal location, presence of common DNA
sequences and different transcription binding sites, and
instead of giving each gene a statistical value it deter-
mines whether members of a gene set S tend to occur
toward the top (or bottom) of the list L, which will corre-
late with phenotype. This approach has been successfully
used in analyzing data from muscle biopsies from dia-
betics vs. healthy controls [7]. The method revealed that
genes involved in oxidative phosphorylation (OXPHOS)
show reduced expression in diabetics, although the aver-
age decrease per gene is only 20%. Thus this method can
identify pathways that may be important, since a 20%
increase or decrease in specific metabolic pathways may
affect the outcome of many disease situations and might
not be detected by the software used to analyze microar-
rays, which usually is set at a two-fold increase or
decrease and a p value of < 0.001. In our previous work
we have emphasized as have others the role of gene
induced following interferon/ribavirin treatment but
ignored genes suppressed or down regulated
In this paper we present a reanalysis of data from a large
clinical trials, Virahep C, in which DNA microarrays were
performed on PBMC from 68 patients receiving a regimen
of interferon-alpha 2a (Pegasys)/ribavirin. In particular we
noted the suppression of gene transcription in the riboso-
mal proteins-eukaryotic translation and elongation factor
pathways.
Materials and methods
Patient treatment and samples
The patient samples used in this study have previously
been described [5]. Approval was received from the
Indiana University Human Subjects Committee.
RNA extraction
Peripheral Blood Mononuclear Cell (PBMC) Preparation
and RNA extraction were as previously described [5,8,9].
RNA labeling and hybridization
Preparation of cDNA, cRNA, and labeling were carried
out according to the protocols recommended by Affy-
metrix in the GeneChip
® Expression Analysis Technical
Manual (Affymetrix, Santa Clara, CA), as previously
described [9].
Array analysis and data processing
The Human Genome U133A microarray containing
22,000 genes was used. The microarrays were scanned
using a dedicated Model 3000 scanner, controlled by
Affymetrix Microarray Suite 5 software (MAS5). Global
scaling to a target intensity of 1,000 normalized the
average intensity on each array. Data were exported
from MAS5 into a custom-designed database (MicroAr-
ray Data Portal) at the Center for Medical Genomics
(IUPUI, Indianapolis). For GSEA analysis no filters were
applied to the gene sets, thus all 22,000 genes at each
time point were used for this analysis
GSEA analysis
We used the GSEA software [10] to identify pathways
that appeared to be over expressed in one or other of
our phenotypic classes. GSEA evaluates a query micro-
array dataset using a collection of gene sets. The Q
value for determining significance was an FDR of < 0.25
Results
We have previously reported that the transcription of a
large number of genes is induced or increased above
background in PBMC harvested from patients with hepa-
titis C during the course of treatment with pegylated-
Interferon-alpha (Pegasys) and ribavirin [5,8] Although
the transcription of an equal number of genes is down-
regulated we have not previously attempted to classify
them by pathway analysis. We have reanalyzed this data
using alternative methods of analysis including GSEA
[10], and other methods that classify genes by pathways
rather than as individual genes. The results of GSEA ana-
lysis are presented in Table 1 using a False Detection
Rate (FDR) calculation of < 0.025 for both pathways up
regulated and down regulated, using the latest Kegg and
Reactome classification. The number of pathways
induced declines by day 7 reflecting the return to near
normal levels of gene transcription within a week of initi-
ating treatment and the transient nature of much of the
interferon response [8]. Day 28 was the last day in which
data was available. The major pathways induced are
DNA sensing pathways and the RIG-I like receptor sig-
naling pathway reflecting binding of dsRNA to toll -like
receptors. The only pathway down regulated at the level
of FDR, 0.25 in this group of patients following treatment
is the ribosomal pathway including ribosomal proteins
initiation factors and elongation factors required for pro-
tein synthesis. The down regulated genes and fold differ-
ence following treatment at day 1 and 2 are presented in
Table 2 and Table 3.
Figure 1(a-e) present heat map of the ribosomal pro-
teins and other genes related to translation of proteins
at the various times during treatment compared to
before treatment.
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Page 2 of 7Table 1 PBMC treated with IFN/ribavirin.
Day 1 enrichment # of genes
Pathway SIZE FDR
q-val
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 31 0.00
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 40 0.00
Table 1 PBMC treated with IFN/ribavirin. (Continued)
KEGG_PROTEASOME 41 0.02
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 70 0.02
KEGG_LYSOSOME 88 0.04
KEGG_TRYPTOPHAN_METABOLISM 17 0.04
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 21 0.06
KEGG_CITRATE_CYCLE_TCA_CYCLE 25 0.09
KEGG_CHEMOKINE_SIGNALING_PATHWAY 104 0.15
KEGG_LEISHMANIA_INFECTION 51 0.15
KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT 27 0.21
KEGG_APOPTOSIS 64 0.20
KEGG_PPAR_SIGNALING_PATHWAY 26 0.20
Day 1 down regulated
KEGG_RIBOSOME 76 0.14
Day 2 enrichment
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 40 0.00
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 31 0.00
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 69 0.00
KEGG_LYSOSOME 88 0.02
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 23 0.04
KEGG_PROTEASOME 41 0.06
KEGG_CHEMOKINE_SIGNALING_PATHWAY 103 0.08
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 95 0.12
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 37 0.15
KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT 27 0.15
KEGG_APOPTOSIS 65 0.19
Day 2 down regulated
KEGG_RIBOSOME 76 0.15
Day 7 enrichment
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 39 0.00
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 30 0.00
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 66 0.09
KEGG_APOPTOSIS 61 0.15
Day 7 down regulated
KEGG RIBOSOME 76 0.20
Day 14 enrichment
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 39 0.00
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 31 0.00
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 67 0.13
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 21 0.18
KEGG_PROTEASOME 41 0.22
Day 14 down regulated
KEGG_RIBOSOME 76 0.18
Day 28 enrichment
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 38 0.00
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 30 0.00
Day 28 down regulated
KEGG_RIBOSOME 76 0.25
Table 2 List of ribosomal genes down regulated at day 1
and day 2 with fold difference.
Ribosomal protein Day 1 Day 2
RPL10 -1.67 -1.45
RPL10 -1.58 -1.47
RPL10A -1.60 -1.52
RPL13 -1.87 -1.65
RPL13 -1.75 -1.57
RPL13 -1.58 -1.48
RPL13 -1.49 -1.46
RPL13 -1.50 -1.41
RPL13A -1.53 -1.41
RPL15 -1.60 -1.46
RPL18 -1.61 -1.51
RPL18A -2.06 -1.52
RPL22 -1.79 -1.63
RPL27AP -1.68 -1.44
RPL29 -1.87 -1.50
RPL29 -1.71 -1.45
RPL3 -2.13 -1.74
RPL3 -1.62 -1.53
RPL3 -1.58 -1.50
RPL3 -1.57 -1.46
RPL35 -1.37 -1.36
RPL35A -1.58 -1.37
RPL36 -1.53 -1.31
RPL4 -1.78 -1.72
RPL4 -1.83 -1.77
RPL4 -1.61 -1.56
RPL4 -1.83 -1.77
RPL6 -1.42 -1.35
RPL8 -1.71 -1.52
RPLP0 -1.89 -1.65
RPLP0 -1.47 -1.37
RPS10L -1.53 -1.48
RPS14 -1.90 -1.67
RPS16 -1.57 -1.48
RPS19 -1.52 -1.32
RPS19 -1.45 -1.30
RPS2 -1.80 -1.34
RPS2 -1.60 -1.43
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proteins and translation factors. A cluster at the top or
bottom of the graph indicates significance. Unlike many
other pathways, the suppression of ribosomal proteins
and translation factors remains constant through out
the treatment period. Although it is weaker at day 7, 14
etc., when much of the interferon/ribavirin effect has
worn off.
Discussion
Treatment of HCV patients with pegylated interferon
and ribavirin results in a suppression of expression of
mRNA for ribosomal proteins and factors involved in
protein synthesis, in PBMC isolated from patients. This
suppression is global for ribosomal proteins and eukar-
yotic translation factors and persists through out the
treatment period up to 28 days. The extent of down reg-
ulation is approximately 50%.
We have previously reported the down regulation of a
few individual ribosomal proteins and translation factors
in PBMC in vitro and in vivo [5,9] following treatment
with Interferon/ribavirin. In this paper we show that
this is a global effect on the transcription of ribosomal
protein genes. We have examined the effect of ribavirin
alone on PBMC in vitro and find some decrease in
mitochondrial ribosomal protein transcription but not
on cytoplasmic ribosomal proteins (data not shown).
Jiang et al. [11] reported the suppression of ribosomal
protein L23 transcription during growth of a melanoma
in culture treated with interferon alpha, beta and
gamma but in the absence of ribavirin.
Meier et al. 2003 [12] reported the inhibition of DNA,
RNA and protein synthesis in vitro on PBMC treated
with PHA in the presence of high doses of ribavirin. This
was a general effect and could be reversed by the addition
of guanosine. A thorough analysis by Wadell et al. [13]
shows a few ribosomal protein genes as being down regu-
lated by IFN-beta and IFN-gamma in PBMC, although
not by IFN-alpha. However the fold cut off used in these
experiments as in our earlier experiments would not pick
up the whole pathway. Thus it is likely that the combina-
tion of Interferon and ribavirin specifically affects tran-
scription of the protein synthetic apparatus.
Unlike other genes affected by interferon/ribavirin
treatment where we see transient changes in ISGs 6 days
after interferon treatment, the down regulation of tran-
scription of ribosomal proteins appears to be quite
constant.
Interferon by itself has previously been shown to inhibit
protein synthesis in a specific manner. This is through the
dsRNA pathway in which RNAse L is activated and
degrades viral RNA [14,15]. However it is unlikely that
this down regulation of ribosomal protein gene mRNA is
the result of non-specific RNA degradation since there is
no effect over all in amounts of specific RNA in the cell as
judged by the large number of genes (the majority) not
affected by interferon/ribavirin treatment.
PKR an interferon induced (and activated) enzyme has
been shown to phosphorylate eukaryotic initiation factor
(EIF2) resulting in inhibition of viral protein synthesis
[16]. Phosphorylation of eIF2 may have an effect on over-
all protein synthesis, however this is unlikely the case
here since there is no evidence for general inhibition of
protein synthesis. The expression of most genes is con-
stant, and only a small percentage are either induced or
suppressed. That viral protein synthesis in inhibited is
shown by the decrease in viral titer during treatment in
responding patients [5]. However the decrease in
Table 2 List of ribosomal genes down regulated at day 1
and day 2 with fold difference. (Continued)
RPS28 -1.69 -1.54
RPS3 -1.52 -1.35
RPS5 -2.02 -1.82
RPS6 -1.55 -1.47
RPS6 -1.41 -1.38
RPS7 -1.45 -1.35
RPS8 -1.56 -1.55
RPS9 -1.46 -1.33
RPS9 -1.47 -1.37
(average from 68 patients including non-responders
Table 3 Elongation and Initiation factors down regulated
Elongation factor Day 1 Day 2
EEF1B2 -1.69 -1.69
EEF1D -1.67 -1.53
EEF1G -1.68 -1.62
EEF1G -1.68 -1.61
EEF1G -1.68 -1.62
EEF2 -1.95 -1.76
EEF2 -1.70 -1.54
Initiation factor
EIF2AK3 -1.50 -1.41
eIF3k -1.30 -1.29
eIF3k -1.26 -1.28
eIF3k -1.18 -1.21
EIF3S5 -1.52 -1.53
EIF3S6IP -1.90 -1.87
EIF3S7 -1.38 -1.38
EIF3S8 -1.19 -1.27
EIF4B -2.20 -1.97
EIF4B -2.38 -2.07
EIF4B -1.58 -1.42
EIF5B -1.31 -1.36
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Page 4 of 7ribosomal protein gene transcription occurs even in non-
responding patients, although to a slightly lower level.
This is in keeping with our previous data in which we
have shown that in non-responsive patients there is a
general blunting of the interferon/ribavirin effect [5].
MicroRNAs have been implicated in regulation of
immune response in lymphocytes and in particular
miRNA-146a has been shown to inhibit by a feed back
mechanism the expression of interferon inducible genes.
However a search of known microRNAs has not shown
any relationship to ribosomal mRNA or Eukaryotic
translation factors. It is possible that unknown micro-
RNAs interact with common sequences in these genes
and suppress transcription or degrade these RNAs. How-
ever this is purely speculative. We also were unable to
find any common transcriptional regulatory sequence
upstream of these genes. Previous reports [17-19] have
indicated a possible role for c-myc in regulating riboso-
mal protein transcription, however level of c-myc at the
transcription level is unaffected by interferon/ribavirin in
our analysis. It is likely that as cells slow down in growth,
and undergo apoptosis that the rate of ribosomal protein
Figure 1 Heat map of ribosomal protein and translation factor pathway.H e a tm a pf r o md a y1 ,2 ,7 ,1 4a n d2 8d a y sa f t e rt r e a t m e n t
initiation.
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decrease. We have previously noted (unpublished data)
that myc transcription is significantly down regulated in
a b-cell line, Daudi following treatment with interferon-
alpha. Thus the decrease reported here might reflect a
decrease in ribosomal protein transcription in one class
of immune cells.
The finding of a general decrease in the protein transla-
tion machinery would be an effective way of inhibiting
virus. Viral load decrease often occurs in vivo a few days
after the initial treatment with interferon/ribavirin. How-
ever this drug combination may also partially inhibit host
protein synthesis in general, and lead to a variety of side
effects in the patients. This could in part be an explanation
for the flu like symptoms and anemia often seen in
patients undergoing treatment with interferon/ribavirin.
Whether this is due to interferon alone, or only occurs in
the presence of ribavirin is not clear, although experiments
in which PBMC were treated only with ribavirin did not
show this effect on ribosomal proteins. However the levels
used in these experiments may have been too low. This
effect was not found in other cell lines treated with inter-
feron in vitro and thus may be unique to PBMC [20] or to
the combination treatment.
Conclusions
During treatment of hepatitis C patients with interferon/
ribavirin there is up regulation and down regulation of
Figure 2 Enrichment plot of Ribosomal proteins and translation factors at day 1 after initiation of treatment.
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Page 6 of 7transcription of many genes. In this analysis we show
that the genes for ribosomal proteins, and eukaryotic
transcription and translation factors are down regulated
at all time points measured (day 1,2,7,14, and 28). Down
regulation of these genes has not been found in other
cell types treated with interferon alone in vitro. We sug-
gest that these data may explain in part the side effects
often noted following interferon/ribavirin treatment as
well as an early inhibition of viral replication.
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